# US 2016/0256487 A1 · Polyclonal gamma delta t cells for immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256487 A1
- Document ID: US20160256487A1
- Status: Published application
- Kind: A1
- Application number: 15/031,610
- Filed: 2014-10-24
- Published: 2016-09-08
- Earliest claimed: 2013-10-25
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, the University of Texas System
- Inventors: Laurence J.N. COOPER; Drew C. DENIGER
- Web page: https://patentgrep.com/patent/US20160256487A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- A61K 40/46: Viral antigens
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- A61K 2039/572: {cytotoxic response}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/54: Pancreas
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2502/11: blood or immune system cells
- C12N 2502/99: genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein is a method of expanding clinically-relevant quantities of polyclonal γδ T cells that have anti-tumor, anti-viral, and anti-bacterial reactivity. Polyclonal γδ T cells can target a variety of tumors, including solid tumors as well as other conditions, such as viral and bacterial infections.

## Claims

### Claim 1

A cell composition comprising at least about 109 purified γδ T cells, wherein the γδ T cells:
(a) are of the Vδ1, Vδ2, and Vδ1negVδ2neg TCR subsets;
(b) have essentially identical genetic material; and
(c) do not contain a chimeric antigen receptor.

### Claim 2 (depends on 1)

The cell composition of claim 1, wherein the composition does not contain NK cells or αβ T cells.

### Claim 3 (depends on 1)

The cell composition of claim 1, wherein the γδ T cells express CD3.

### Claim 4 (depends on 1)

The cell composition of claim 1, wherein the γδ T cells do not express CD57 or PD-1.

### Claim 5 (depends on 1, 2, 3, 4)

A pharmaceutical composition comprising a cell composition according to any one of claims 1-4 and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 1, 2, 3, 4)

A method of producing a cell composition according to any one of claims 1-4 comprising:
(a) obtaining a sample of cells comprising a first polyclonal γδ T-cell population; and
(b) culturing the first polyclonal γδ T-cell population with artificial antigen presenting cells (aAPCs) in the presence of interleukin-2 (IL-2) and interleukin-21 (IL-21), thereby producing a cell composition according to any one of claims 1-4.

### Claim 7 (depends on 6)

The method of claim 6, further comprising depleting the sample of cells of CD56- and TCRαβ-expressing cells.

### Claim 8 (depends on 6)

The method of claim 6, wherein the sample of cells is a peripheral blood sample, an umbilical cord blood sample, or a tissue sample.

### Claim 9 (depends on 6)

The method of claim 6, wherein the sample of cells is obtained from a single subject.

### Claim 10 (depends on 6)

The method of claim 6, wherein the first polyclonal γδ T-cell population comprises about 104 to about 106 γδ T cells.

### Claim 11 (depends on 6)

The method of claim 6, wherein the aAPCs are transgenic K562 cells.

### Claim 12 (depends on 6)

The method of claim 6, wherein the aAPCs express CD137L.

### Claim 13 (depends on 12)

The method of claim 12, wherein the aAPCs further express CD19, CD64, CD86, and mIL15.

### Claim 14 (depends on 11)

The method of claim 11, wherein the aAPCs express at least one anti-CD3 antibody clone.

### Claim 15 (depends on 14)

The method of claim 14, wherein the at least one anti-CD3 antibody clone is OKT3 and/or UCHT1.

### Claim 16 (depends on 14)

The method of claim 14, wherein the aAPCs express OKT3 and UCHT1.

### Claim 17 (depends on 6)

The method of claim 6, wherein the aAPCs are inactivated.

### Claim 18 (depends on 17)

The method of claim 17, wherein the aAPCs are irradiated.

### Claim 19 (depends on 6)

The method of claim 6, wherein the aAPCs have been tested for and confirmed to be free of infectious material.

### Claim 20 (depends on 6)

The method of claim 6, wherein culturing the first polyclonal γδ T-cell population with aAPCs comprises culturing the cells at a ratio of about 10:1 to about 1:10 (γδ T cells to aAPCs).

### Claim 21 (depends on 6)

The method of claim 6, wherein the aAPC in the culture are replenished every week.

### Claim 22 (depends on 6)

The method of claim 6, wherein culturing the first polyclonal γδ T-cell population with aAPCs comprises culturing for at least 2 weeks.

### Claim 23 (depends on 22)

The method of claim 22, wherein culturing the first polyclonal γδ T-cell population with aAPCs results in at least a 100-fold increase in the number of polyclonal γδ T cells.

### Claim 24 (depends on 6)

The method of claim 6, wherein step (b) further comprises treating the culture with an aminobisphosphonate.

### Claim 25 (depends on 6)

The method of claim 6, wherein the γδ T cells are human γδ T cells.

### Claim 26 (depends on 1, 2, 3, 4)

A method of producing a cell composition according to any one of claims 1-4 comprising:
(a) obtaining a sample of cells comprising a first polyclonal γδ T-cell population; and
(b) culturing the first polyclonal γδ T-cell population in the presence of at least one anti-CD3 antibody clone and further in the presence of interleukin-2 (IL-2) and interleukin-21 (IL-21), thereby producing a cell composition according to any one of claims 1-4.

### Claim 27 (depends on 26)

The method of claim 26, further comprising depleting the sample of cells of CD56- and TCRαβ-expressing cells.

### Claim 28 (depends on 26)

The method of claim 26, wherein the at least one anti-CD3 antibody clone is OKT3 or UCHT1.

### Claim 29 (depends on 26)

The method of claim 26, wherein the at least one anti-CD3 antibody clone is OKT3 and UCHT1.

### Claim 30 (depends on 26)

The method of claim 26, wherein the at least one anti-CD3 antibody clone is expressed on the surface of an aAPC.

### Claim 31 (depends on 26)

The method of claim 26, wherein the at least one anti-CD3 antibody clone is on the surface of a microbead.

### Claim 32 (depends on 26)

The method of claim 26, wherein culturing the first polyclonal γδ T-cell population comprises culturing for at least 2 weeks.

### Claim 33 (depends on 1, 2, 3, 4, 5)

A method of treating a disease in a patient comprising administering an effective amount of a cell composition according to any one of claims 1-4 or a pharmaceutical composition according to claim 5.

### Claim 34 (depends on 33)

The method of claim 33, wherein the disease is cancer.

### Claim 35 (depends on 34)

The method of claim 34, wherein the cancer is T-cell ALL, B-ALL, CML, colon cancer, ovarian cancer, neuroblastoma, a brain tumor, or pancreatic cancer.

### Claim 36 (depends on 33)

The method of claim 33, wherein the disease is a viral infection.

### Claim 37 (depends on 36)

The method of claim 36, wherein the viral infection is cytomegalovirus (CMV), Epstein-Barr virus (EBV), or human immunodeficiency virus (HIV).

### Claim 38 (depends on 33)

The method of claim 33, wherein the disease is a bacterial infection.

### Claim 39 (depends on 38)

The method of claim 38, wherein the disease is sepsis.

### Claim 40 (depends on 33)

The method of claim 33, wherein the cell composition is allogeneic to the patient.

### Claim 41 (depends on 33)

The method of claim 33, wherein the cell composition is autologous to the patient.

### Claim 42 (depends on 34)

The method of claim 34, wherein the patient has undergone a previous anti-cancer therapy.

### Claim 43 (depends on 42)

The method of claim 42, wherein the patient is in remission.

### Claim 44 (depends on 42)

The method of claim 42, wherein the patient is free of symptoms of the cancer but comprises detectable cancer cells.

### Claim 45 (depends on 33)

The method of claim 33, wherein the patient is a human patient.

### Claim 46 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of treating a disease in a patient comprising:
(a) producing a cell composition according to the method of any one of claims 6-25; and
(b) administering an effective amount of said cell composition to a patient in need thereof.

### Claim 47 (depends on 1, 2, 3, 4, 5)

A composition comprising a cell population according to any one of claims 1-4 or a pharmaceutical composition according to claim 5, for use in the treatment of a disease in a patient.

### Claim 48 (depends on 47)

The composition of claim 47, wherein the disease is cancer.

### Claim 49 (depends on 48)

The composition of claim 48, wherein the cancer is T-cell ALL, B-ALL, CML, colon cancer, ovarian cancer, or pancreatic cancer.

### Claim 50 (depends on 47)

The composition of claim 47, wherein the disease is a viral infection.

### Claim 51 (depends on 50)

The composition of claim 50, wherein the viral infection is cytomegalovirus (CMV), Epstein-Barr virus (EBV), or human immunodeficiency virus (HIV).

### Claim 52 (depends on 47)

The composition of claim 47, wherein the disease is a bacterial infection.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the disease is sepsis.

### Claim 54 (depends on 47)

The composition of claim 47, wherein the cell composition is allogeneic to the patient.

### Claim 55 (depends on 47)

The composition of claim 47, wherein the cell composition is autologous to the patient.

### Claim 56 (depends on 1, 2, 3, 4)

Use of a cell population according to any one of claim 1-4 in the manufacture of a medicament for the treatment of a disease.
